Nebenwirkungen · Brilique
Brilique 60 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11–12
HOS-123556 · Präparat HOS-095701
11 Non-CABG related bleeding and non-procedural related bleeding: Ticagrelor and clopidogrel did not differ in non-CABG PLATO-defined Major Fatal/Life-threatening bleeding, but PLATO-defined Total Major, TIMI Major, and TIMI Major + Minor bleeding were more common with ticagrelor. Similarly, when removing all procedure related bleeds, more bleeding occurred with ticagrelor than with clopidogrel (Table 2). Discontinuation of treatment due to non- procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p<0.001).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 24c9f526026a0b6ebe3de922e05447ae3f094ce0ceed66f68407be8bab57cb79 · Zeichen 9541–10087 im Abschnitt